Common variants of the TLR9 gene influence the clinical course of HBV infection

Molecular Medicine Reports

Volumn 2, Issue 2, 2009, Pages 277-281

  Jia, Nina ^a   Xie, Qing ^a   Lin, Lanyi ^a   Gui, Honglian ^a   Wang, Hui ^a   Jiang, Shan ^a   Yu, Hong ^a   Guo, Qing ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Cirrhosis; Hepatitis B virus; Innate immunity; Single nucleotide polymorphisms; Toll like receptor 9

Indexed keywords

TOLL LIKE RECEPTOR 9;

ADULT; ARTICLE; CHINESE; CHRONIC HEPATITIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEREDITY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

HEPATITIS B VIRUS;

EID: 69249125360     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000096     Document Type: Article

References (35)

1. Fattovich G, Bortolotti F and Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48: 335-352, 2008.
2. Bataller R, North KE and Brenner DA: Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37: 493-503, 2003. (Pubitemid 36258768)
3. Hirose A, Ono M, Saibara T, et al: Angiotensin II type 1 receptor blocker inhibits fibrosis in rat non-alcoholic steatohepatitis. Hepatology 45: 1375-1381, 2007. (Pubitemid 46918321)
4. Xiao F, Wei H, Song S, Li G and Song C: Polymorphisms in the promoter region of the angiotensinogen gene are associated with liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 21: 1488-1491, 2006. (Pubitemid 44154722)
5. Barchet W, Cella M and Colonna M: Plasmacytoid dendritic cells-virus experts of innate immunity. Semin Immunol 17: 253-261, 2005. (Pubitemid 40981931)
6. Szabo G, Dolganiuc A and Mandrekar P: Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 44: 287-298, 2006. (Pubitemid 44214866)
7. Cooper CL, Davis HL, Morris ML, et al: CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24: 693-701, 2004.
8. Xu N, Yao HP, Sun Z and Chen Z: Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacol Sin 29: 239-244, 2008. (Pubitemid 351178417)
9. Schroder NW, Diterich I, Zinke A, et al: Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 175: 2534-2540, 2005. (Pubitemid 41113865)
10. Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B and Mira JP: The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 41: S408-S415, 2005. (Pubitemid 41598297)
11. Smirnova I, Mann N, Dols A, et al: Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 100: 6075-6080, 2003. (Pubitemid 36576933)
12. Van der Graaf CA, Netea MG, Morre SA, et al: Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 17: 29-34, 2006.
13. Agnese DM, Calvano JE, Hahm SJ, et al: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186: 1522-1525, 2002.
14. Barber RC, Aragaki CC, Rivera-Chavez FA, Purdue GF, Hunt JL and Horton JW: TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet 41: 808-813, 2004.
15. Montes AH, Asensi V, Alvarez V, et al: The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 143: 404-413, 2006.
16. Tal G, Mandelberg A, Dalal I, et al: Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189: 2057-2063, 2004. (Pubitemid 38692286)
17. Hawn TR, Verbon A, Lettinga KD, et al: A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires' disease. J Exp Med 198: 1563-1572, 2003. (Pubitemid 37467170)
18. Schott E, Witt H, Neumann K, et al: A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 46: 198-205, 2007. (Pubitemid 47021254)
19. Isogawa M, Robek MD, Furuichi Y and Chisari FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79: 7269-7272, 2005. (Pubitemid 40677357)
20. Duan XZ, Wang M, Li HW, Zhuang H, Xu D and Wang FS: Decreased frequency and function of circulating plasmacytoid dendritic cells (pDC) in HBV infected humans. J Clin Immunol 24: 637-646, 2004. (Pubitemid 40933115)
21. Van der Molen RG, Sprengers D, Binda RS, et al: Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40: 738-746, 2004. (Pubitemid 39265597)
22. Bochud P-Y, Hersberger M, Taffe P, et al: Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 21: 441-446, 2007. (Pubitemid 46263254)
23. De Andrade DR Jr and De Andrade DR: The influence of the human genome on chronic viral hepatitis outcome. Rev Inst Med Trop Sao Paulo 46: 119-126, 2004.
24. Wang FS: Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol 9: 641-644, 2003.
25. Chong WP, To YF, Ip WK, et al: Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 42: 1037-1045, 2005. (Pubitemid 43112670)
26. Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenefelde KH and Rittner C: A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 111: 579-582, 1998.
27. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA and Mehal WZ: Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46: 1509-1518, 2007. (Pubitemid 350155533)
28. Huang XX, McCaughan GW, Shackel NA and Gorrell MD: Upregulation of proproliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis. Liver Int 27: 960-968, 2007.
29. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
30. Takeshita F, Leifer CA, Gursel I, et al: Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167: 3555-3558, 2001. (Pubitemid 32910795)
31. Offner PJ, Moore EE and Biffl WL: Male gender is a risk factor for major infections after surgery. Arch Surg 134: 935-940, 1999.
32. Kast RE: Predominance of autoimmune and rheumatic diseases in females. J Rheumatol 4: 288-292, 1977.
33. Marriott I, Bost KL and Huet-Hudson YM: Sexual dimorphism in expression of receptors for bacterial lipopolysaccharides in murine macrophages: a possible mechanism for gender-based differences in endotoxic shock susceptibility. J Reprod Immunol 71: 12-27, 2006. (Pubitemid 43975140)
34. Imahara SD, Jelacic S, Junker CE and O'Keefe GE: The influence of gender on human innate immunity. Surgery 138: 275-282, 2005. (Pubitemid 41253811)
35. Berghofer B, Frommer T, Haley G, Fink L, Bein G and Hackstein H: TLR7 ligands induce higher IFN-alpha production in females. J Immunol 177: 2088-2096, 2006. (Pubitemid 44200966)